Colorcon acquires Kollicot Coating Systems line from BASF
Company also advances co-operation to offer superior functional coatings for pharmaceutical tablets.
Colorcon and BASF have signed an agreement to further strengthen their co-operation in the area of pharmaceutical film coatings. As part of this agreement, BASF will sell its Kollicoat IR Coating Systems product line to Colorcon; including the current customer business, inventory and relevant know-how. The addition of the Kollicoat IR Coating Systems complements Colorcon’s existing film coating product line and position as a leading innovator of fully formulated film coating systems and provides Kollicoat IR Coating Systems customers with a wide range of film coating options. Final closure of the transaction is subject to review of the Brazilian competition authorities.
By acquiring the Kollicoat IR Coating Systems, Colorcon further strengthens its existing activities with PVA-based pigmented, ready-to-use film coatings, for use on immediate release forms of pharmaceuticals and dietary supplements. Kelly Boyer, General Manager Coatings at Colorcon, explains: “This sale enables both companies to focus on their core competencies, and further strengthens our existing cooperation.” After final closure of the transaction all existing customers of Kollicoat IR Coating Systems will be served by Colorcon from its worldwide production facilities. Both BASF and Colorcon look forward to the opportunity to expand the cooperation between both companies in the film coating area by combining BASF’s polymer expertise and Colorcon’s formulation and application knowledge. Frank Stein, Vice President Global Segment Management Pharma Solutions at BASF, states: “Customers will benefit from both the exceptional functional performance of the products as well as from Colorcon’s worldwide unique, customized services.BASF will focus on developing and promoting innovative film coating polymers including Kollicoat IR. The transfer of Kollicoat IR Coating Systems does not affect BASF’s Kollicoat IR polymer business.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance